Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences ( ($GILD) ) just unveiled an announcement. On August 10, 2025, Gilead Sciences announced the appointment of Erin Burkhart as ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD) and its peers.

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb from an estimated USD 34.8 billion in 2025 to USD 53.6 billion by 2035. This ...

JPMorgan (NYSE: JPM) told investors in a note Monday that Eli Lilly & Co. (NYSE: LLY) shares are its “top pick” among U.S.